Activation of AMPK or conversely inhibition of mTOR appear therefore as pertinent therapeutic options for the treatment of BCR-ABL expressing malignancies raising the potential use of AMPK activators such as Aca or Metformin in the treatment of refractory CML and Ph(+) acute lymphoblastic leukemia [22]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.